Credit Woes Hit Pharma
Executive Summary
The biggest pharmaceutical companies are least affected by the current credit crisis due to their strong balance sheets and hefty piles of cash, yet even they are finding debt is more expensive and harder to obtain. Big biotechs also have billions of dollars in cash and marketable securities. Smaller, development stage companies, however, are more fragile because their existence depends on their ability to raise money to fund their R&D.Specialty pharma falls in between big pharma and biotech: the group is vulnerable, but not as much as biotech. The lack of access to capital makes doing deals tougher and more expensive.
You may also be interested in...
Big Pharma Needs A Nudge To Make More Deals In Neuroscience Space
Neurology field is a “sleeper” deal category, experts say, with lots of unmet need, scientific advances and even blockbuster opportunities.
Eli Lilly's Oncology Focus
On October 6, Eli Lilly & Co. became the latest pharmaceutical company to jump on the cancer bandwagon, with its $6.5 billion acquisition of ImClone Systems Inc.The deal gives Lilly the royalty stream to one marketed product-cetuximab (Erbitux), plus five additional clinical stage compounds, many of which are biologics. The problem is many of the candidate drugs face stiff competition--and the pharma has severely depleted its cash holdings to get the deal signed.
Eli Lilly's Oncology Focus
On October 6, Eli Lilly & Co. became the latest pharmaceutical company to jump on the cancer bandwagon, with its $6.5 billion acquisition of ImClone Systems Inc.The deal gives Lilly the royalty stream to one marketed product-cetuximab (Erbitux), plus five additional clinical stage compounds, many of which are biologics. The problem is many of the candidate drugs face stiff competition--and the pharma has severely depleted its cash holdings to get the deal signed.